A comparative toxicological study was carried out for etretinate and retinyl palmitate, a naturally occurring retinol, using rats. Hematological and blood biochemical exami nations revealed that etretinate showed lower toxicity and a larger difference between its clinically effective dose and hypervitaminosis A-causing dose, compared with retinyl palmitate. Moreover, electron microscopy of the liver demonstrated a marked accumulation of lipid droplets in the cytoplasm of fat storing cells treated with retinyl palmitate, suggesting that etretinate may be more rapidly metabolized than retinyl palmitate in the liver of the animal.
It is well known that retinoic acid and its derivatives (retinoids) at their clinically ef fective doses cause hypervitaminosis A which is an adverse effect of the substances (1). Also, it has been reported that hypervitami nosis A induced by treatment with various retinoids is considered to be due to their tendency to accumulate in the liver. Such retinoids are finally stored in the liver in the form of retinyl palmitate (2) . On the other hand, etretinate is effective for many kinds of dermal diseases and less toxic than natural retinoids. The present report deals with blood and liver levels of etretinate and retinyl palmitate in rats immediately after adminis tration and during their recovery periods, in addition to hematological findings and electron micrographs of the liver. A short discussion is also presented. The test sub stances, etretinate (ethyl -a#-traps-9-(4 metoxy-2,3,6-trimethyl phenyl)-3,7-dimethyl 2,4,6,8-nonatetraenoate) and retinyl palmi tate, were kindly supplied by Nippon Roche K. K.
Sprague-Dawley male rats, 5 weeks of age, weighing about 140 g, 5 in a group, were treated with etretinate or retinyl palmi tate at a dose of 5 mg/kg or 5.75 mg/kg, respectively, by oral gavage once a day for 4 weeks. Another 2 groups, each consisting of 5 animals, were given nothing or the peanut oil vehicle only. Animals were sacrificed after collecting blood samples 24 hr or 2 weeks after the 4-week adminis tration period.
Hematological examinations were carried out for erythrocyte counts (RBC), leukocyte counts (WBC) (automatic blood corpuscle counter), hemoglobin (Hb) (cyanomethemo globin method) and hematocrit (Ht) (capillary method).
Serum biochemical examinations were done for total protein, A/G ratio, GOT, GPT, LDH, alkaline pos phatase, bilirubin, creatinine, uric acid, BUN, total cholesterol (autoanalyzer, Hitachi 716, Hitachi), triglycerides, phospholipids (auto analyzer, Clinalyzer 6ch, JEOL) and non esterified fatty acids (enzyme method). The serum and liver levels of retinoids were assessed by measuring the corresponding peak heights on HPLC charts. The serum levels of retinoids were determined as retinol.
Prior to liver excision, the animals were fixed by slow perfusion of a fixative of 1.5% glutaraldehyde buffered to pH 7.4 with 0.06 (Table 1) . There was little difference in serum levels of retinol and liver levels of retinol and retinyl palmitate, both 24 hr and 2 weeks after the 4-week treatment period, between the etretinate group and the vehicle control or the untreated control group. Etretinate and its main metabolites, one of which was Ro 10-1670, were detected in neither serum nor liver, both 24 hr and 2 weeks after the 4-week etretinate administration.
Twenty-four hours after retinyl palmitate administration, there was no difference between the serum level of retinol in the untreated group and the vehicle control group, while the liver levels of retinol and retinyl palmitate were markedly increased. After 2 weeks, the liver level of retinol was decreased, while that of retinyl palmitate was further increased to about 1.8 times as high as the level after 24 hr (Table 1) . There were several lipid droplets observed in the cytoplasm of fat-storing cells in the Disse's space of the liver prepared 24 hr after the 4-week etretinate treatment period. The picture was similar to that of the untreated control or the vehicle control livers (not published).
Twenty-four hours after retinyl palmitate administration, many droplets were observed in fat-storing cells. There was no change in the fine structure of cell organelles or nuclei of fat-storing cells by the adminis tration of either etretinate or retinyl palmitate (Fig. I) .
Concerning existing retinoids, it is known that as they tend to accumulate in the liver, hypervitaminosis A appears before the blood level of the retinols reaches a clinically effec tive one (1) . On the other hand, it is reported that hypervitaminosis A does not occur with etretinate at the clinically effective doses for various skin keratoses. As a matter of fact, the therapeutic ratio (the ratio of the incidence rate of hypervitaminosis A to ED50 for papilloma) with etretinate is 10% of that with retinoic acid (3). Mahadevan et al. have reported the accumulation of natural re tinoids as the test results with various retinyl esters and retinol. According to them, the administered retinoids accumulated in the liver eventually as retinyl palmitate, and the liver level of retinyl palmitate was higher at 24 hr post-dose than immediately after admin istration even in the group receiving retinyl palmitate (2) .
In the present study, it was inferred from hematological findings that etretinate was lower in toxicity than retinyl palmitate. The determination of the serum and liver levels of retinoids following administration of etretinate or retinyl palmitate revealed that etretinate was metabolized more rapidly than retinyl palmitate, and the accumulation of etretinate in the liver was very low. The liver level of retinyl palmitate was higher in the 2nd week than at 24th hour after the 4-week retinyl palmitate treatment period, suggesting a high accumulation.
The difference in the accumulation in the liver between etretinate and retinyl palmitate was also demonstrated by electron micro scopy. There was almost no accumulation of lipid droplets in the fat-storing cells of the liver by etretinate administration, while treat ment with retinyl palmitate resulted in an apparent increased number of lipid droplets which might contain retinyl palmitate.
Conjecturing from the extremely low ac cumulation of etretinate in the liver, it can be concluded that the rapid metabolizability of etretinate contributes to the manifestation of lower toxicity such as the small incidence of hypervitaminosis A at the clinically effective dose of etretinate than that of naturally occurring retinoids.
